The Female Health Company's Distributor, Sekunjalo Investments Corporation (PTY)
Ltd., Receives Order for 5 Million FC2 Female Condoms From the Republic of South
Africa Department of Health
CHICAGO, Nov. 22, 2011 /PRNewswire via COMTEX/ -- The Female Health Company
(FHCO- NASDAQ-CM) today announced that its exclusive distributor in the Republic
of South Africa (RSA), Sekunjalo Investments Corporation (PTY) Ltd., has received
an order from the RSA Department of Health (DOH) to supply 5 million FC2 Female
Condoms for delivery as soon as possible. Shipments against the order will begin
before calendar year end.
O.B. Parrish, Chairman and C.E.O. of The Female Health Company, noted that "the
Company applauds South Africa for providing FC2 Female Condoms, a safe, effective
product that gives women options to control their sexual health, particularly
HIV/AIDS prevention".
"We are very encouraged by recent indications of demand growth from customers
that distribute female condoms globally and believe the long-term outlook for the
Company remains positive for three reasons: the feminization of HIV/AIDS, the
complexity of developing easy-to-use alternative prevention methods, and the
emergence of drug resistant strains of sexually transmitted infections (STI's)."
The FC2 Female Condom has been approved by the FDA as a Class III medical device
and has been cleared by the World Health Organization for purchase by U. N.
Agencies.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets
the FC2 Female Condom? (FC2), which is available in the U.S. and in about 120
other countries globally. The Company owns certain worldwide rights to the FC2
Female Condom?, including patents that have been issued in the U.S., the European
Union, Canada, Australia, South Africa, Japan, The People's Republic of China,
Spain, Mexico, Greece, Turkey and the African Regional Intellectual Property
Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho,
Malawi, Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Uganda,
United Republic of Tanzania, Zambia and Zimbabwe. FC2 patent applications are
pending in various countries. The FC2 Female Condom? is the only available
FDA-approved product controlled by a woman that offers dual protection against
sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The
World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this release which are not historical fact are "forward-looking
statements" as that term is defined in the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this release relate to the Company's
long-term outlook and growth in demand for the Company's product. These
statements are based upon the Company's current plans and strategies, and reflect
the Company's current assessment of the risks and uncertainties related to its
business, and are made as of the date of this release. The Company assumes no
obligation to update any forward-looking statements contained in this release as
a result of new information or future events, developments or circumstances. Such
forward-looking statements are inherently subject to known and unknown risks and
uncertainties. The Company's actual results and future developments could differ
materially from the results or developments expressed in, or implied by, these
forward-looking statements. Factors that may cause actual results to differ
materially from those contemplated by such forward-looking statements include,
but are not limited to, the following: product demand and market acceptance;
competition in the Company's markets and the risk of new competitors and new
competitive product introductions; the Company's reliance on its international
partners in the consumer sector and on the level of spending on the female condom
by country governments, global donors and other public health organizations in
the global public sector; the economic and business environment and the impact of
government pressures; risks involved in doing business on an international level,
including currency risks, regulatory requirements, political risks, export
restrictions and other trade barriers; the Company's production capacity,
efficiency and supply constraints; and other risks detailed in the Company's
press releases, shareholder communications and Securities and Exchange Commission
filings, including the Company's Form 10-K for the fiscal year ended September
30, 2010. Actual events affecting the Company and the impact of such events on
the Company's operations may vary from those currently anticipated.
For more information about the Female Health Company visit the Company's website
at femalehealth.com and femalecondom.org. If you would like
to be added to the Company's e-mail alert list, please send an e-mail to
FHCInvestor@femalehealthcompany.com.
SOURCE The Female Health Company |
